Superworth

Palvella Therapeutics profit margin PVLA

Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.

Net margin, 12 months
n/m
a quarter missing
Peer median
10.9%

Palvella Therapeutics' net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024n/an/a
FY2023−57.3%−69.5%
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019−55.0%−58.7%
FY2018−91.9%n/a
FY2017−69.8%−57.7%
FY2016n/an/a
FY2015n/an/a
FY2014n/an/a
FY2014n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24−34.0%n/a−39.1%
Q4 FY23−57.3%n/a−69.5%
Q3 FY23−59.3%n/a−77.7%

Against its peers

Companies in Drug Manufacturers - General nearest Palvella Therapeutics' size, closest first, today.

CompanyProfit margin
PVLAPalvella Therapeuticsn/m
ANIPANI Pharmaceuticals11.1%
PAHCPhibro Animal Health6.6%
HRMYHarmony Biosciences18.9%
ANABAnaptysbion/m
PCRXPacira BioSciences2.0%
PBHPrestige Consumer Healthcare15.6%
OMEROmerosn/m
NRIXNurix Therapeutics42.0%
AMPHAmphastar Pharmaceuticals10.8%
OGNOrganon3.4%
Peer median10.9%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Palvella Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.